Journal Club Rakesh Latchamsetty October 5, 2007.

Slides:



Advertisements
Similar presentations
AKI in Pediatrics Patrick D. Brophy MD Associate Professor
Advertisements

Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Nallasamy K, Jayashree M, Singhi S, Bansal A
Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
Automated, Electronic Alerts for AKI A Randomized, Controlled Trial F. Perry Wilson, MD MSCE NephJC Live Journal Club Philadelphia, PA 11/15/14.
REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
A Randomized Trial of Protocol-Based Care for Early Septic Shock Andrea Caballero, MD January 15, 2015 LSU Journal Club The ProCESS Investigators. N Engl.
Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: A pilot double- blind, randomized controlled trial Critical Care Medicine.
Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis ALBION.
Acute Kidney Injury. 49 year old man was a single vehicle MVC in which he was ejected. His injuries include: 49 year old man was a single vehicle MVC.
Journal Club Naudia N. Lauder, M.D. Evan J. Lipson, M.D. David T. Majure, M.D., M.P.H.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
Contrast Induced Nephropathy: Predictors, Prevention, and Management Columbia University Medical Center Cardiovascular Research Foundation Roxana Mehran,
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Hepatorenal Syndrome Dr Allister J Grant Leicester Liver Unit
A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy.
Clinical Outcomes with Newer Antihyperglycemic Agents
Sarah Struthers, MD March 19, 2015
强 生 Cordis 学 院 Cordis 百家病例论坛 PCI for patients with Chronic Renal Dysfunction Dr. Liyi First Affiliated Hospital of Sun Yat-sen University.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Radiocontrast Nephropathy Jason S. Finkelstein, M.D. Tulane University HSC Division of Cardiology 3/2/04.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
CARE Cardiac Angiography in REnally impaired patients: A comparison between Iodixanol (Visipaque) and Iopamidol (Isovue) in high risk patients for contrast.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Gestione dell’insufficienza renale nelle sindromi coronariche: prima e dopo lo studio emodinamico Rossana Fusco Dipartimento Cardio-Toraco-Vascolare A.De.
ACUTE RENAL FAILURE 吳志仁 醫師 馬偕醫院 腎臟內科. Definition An increase Cr. ≧ 0.5 mg/dl per day An increase of more than 50 % over baseline Cr. A reduction in calculated.
Hexabrix Key Clinical Review Liss, 2006 Mid-Year Sales Meeting Bloomington, IN July 13 th – 17 th.
Prevention of Serious Adverse Outcomes Following Angiography (PRESERVE) Trial Steven D. Weisbord MD, MSc.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Acetylcysteine for the prevention of Contrast- induced nephropaThy (ACT) Trial: The ACT Trial Investigators Presenter: Otavio Berwanger (MD; PhD) Chair.
A.Rasoolzadeh MD. Contrast induced nephropathy (CIN): A kind of reversible AKI as a rise in serum creatinine (by 25%) during of h after receipt.
Retrospective Monocentric 10-Year Analysis Of Sepsis-Associated Acute Kidney Injury: Impact On Outcome, Dialysis Dose And Residual Renal Function 1 Vincenzo.
Sodium Bicarbonate therapy for Prevention of contrast induced nephropathy of contrast induced nephropathy -A Meta-analysis American Journal of Kidney Diseases,
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
CONTRAST NEPHROPATHY MARC J. SCHWEIGER Director Cardiac Catheterization Laboratories, Baystate Medical Center.
1 CONTRAST - INDUCED ACUTE RENAL INJURY. Acute Renal Failure Nephrotoxic ATN Endogenous Toxins –Heme pigments (myoglobin, hemoglobin) –Myeloma light chains.
Hydration for Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention
Angela Aziz Donnelly April 5, 2016
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Clinical Outcomes with Newer Antihyperglycemic Agents
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Early high-dose Rosuvastatin for
Contrast Awareness: Why and When Do we Worry?
Clinical Research at the VA
VA Cooperative Studies Program Trial # 578
Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention.
Mannitol and current trends in fluid management
Hexabrix Key Clinical Review Mehran, 2009
Bệnh thận do thuốc cản quang
European Heart Association Journal 2007 April
Fewer PCIs After Public Reporting Changes in NY
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
End point Fenoldopam, n (%) Dopamine, n (%) p
Erasmus MC, Thoraxcenter
What oral antiplatelet therapy would you choose?
Dr Donal O’Donoghue National Clinical Director for Kidney Care
Presentation transcript:

Journal Club Rakesh Latchamsetty October 5, 2007

Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Lee P, Chou K, Liu C, Mar G, Chung H, et al. JACC, Sept. 11, 2007

Why is Renal Impairment Important? CKD is associated with 3 year increased mortality and increased CV events 1 Background 1 Go AS, Hsu C, et al. NEJM :

3 Year Outcomes with CKD Background Go AS, Hsu C, et al. NEJM :

Why is Renal Impairment Important? Renal insufficiency increases mortality in patients admitted with ACS 2 Background 2 Eagle KA, Fox KA et al. JAMA :

Background Eagle KA, Fox KA et al. JAMA :

Even Temporary ARF has Worse Prognosis Background 6 month mortality in patients admitted with ACS is worse with acute renal failure, regardless of improvement in function 3 3 Latchamsetty R, Eagle KA, et al. AJC (7)

6 Month outcomes following ACS admission A – no change in creatinine B – Temporary rise in Cr C – Sustained rise Cr Background A B C Latchamsetty R, Eagle KA, et al. AJC (7)

ARF Following PCI has Worse Prognosis 4 Background 4 Rihal CS, Holmes DR, et al. Circulation (19):

Mechanism of CIN Background Multifactorial process -Vasoconstriction at the corticomedullary junction -Impairs autoregulatory capacity of kidney through loss of NO production -Direct tubular toxicity -Osmotic diuresis

Risk Factors for Developing CIN Background Pre-existing renal disease Diabetes Amount and type of contrast

Mechanism of CIN Background Tumlin J, McCullough P, et al. AJC (6A)

Methods to reduce CIN: – IVF – Low-osmolality contrast – Double dose mucomyst – Reducing contrast – Sodium Bicarbonate – CVVH Background

Low Osmolar Contrast Originally ionic monomers: hyperosmolar – 1500 to 1800 mOsm/kg Low-osmolar monomers of iodinated benzene rings (iohexol/omnipaque, iopamidol) – 600 to 850 mOsm/kg Nonionic dimer of benzene rings (iodaxinol/visipaque) – 290 mOsm/kg Background

N-Acetylcysteine Background Scavenges oxygen free radicals Shown to reduce incidence of CIN, dose- dependent effect 6 Some data on mortality reduction 6 6 Marenzi G, Bartorelli A, NEJM (26):

CVVH Previous study showing CVVH can reduce renal failure and improve outcomes in CKD 7 – Only elective cath/pci – Compared to NS alone Primary endpoint: 25% increase in Cr – 5 vs 50% (P<.001) One year mortality also decreased – 10 vs 30% (p=.01) Background 7 Marenzi G, Bartorelli A, et al. NEJM :

To determine whether prophylactic hemodialysis reduces CIN after coronary angiogram Objective

Inclusion Criteria Consecutive patients at Kaohsiung Veterans GH, Taiwan referred for coronary angiography > 20 years old Creatinine >3.5 mg/dl Methods

Exclusion Criteria Pregnancy or lactation Contrast in last 7 days Metformin or NSAIDs in last 48 hrs ESRD or renal txp Unstable new diabetes “Severe concomitant disease” Adverse contrast reaction in the past Methods

Protocol All given NS 6 hours before and 12 hours after cath Randomized to HD or not (control) Dialysis catheter placed before angiography Cath performed with nonionic iohexol (omnipaque) Dialysis performed as soon as possible after cath No fluid removal during dialysis Methods

Measurements CrCl by 24 hour urine before and on 4 th day after Serum creatinine on admission, day 4, and throughout hospitalization Need for emergent dialysis – Oliguria for 48 hours despite 1,000mg lasix per day – K + > 6 mEq/L Methods

Statistics Study was designed for significance of 5% and 90% power Required about 34 subjects in each group To compare baseline values: – Fisher exact test for categorical – Student unpaired t test for continuous Multiple regression to analyze variables affecting decrease in CrCl Methods

Endpoints Primary endpoint: change in CrCl between baseline and day 4 Secondary enpoints: – Change in Cr between baseline and day 4 – Peak Cr level – Cr level at discharge – Requirement of emergent or permanent dialysis Methods

Sample Space 3,724 consecutive patients receiving cath - 3,406 without CKD with ESRD with Cr < refused received NSAIDs/mucomyst/contrast 82Enrolled Results

Demographics The 2 groups were well matched Results

Change in Creatinine Clearance Results

Change in Creatinine Results

Factors associated with change in creatinine… Results

Further Outcomes 1 vs 14 needed temporary dialysis 5 control patients required permanent dialysis after discharge 2 vs 18 had increase in creatinine greater than 1 at discharge Results

Statistically Speaking… Cr increased > 1 at discharge: – control (45%) vs dialysis (5%), p<.001 – NNT = 2.5 Required maintenance dialysis after discharge: – control (13%) vs dialysis (0%) – NNT = 8 Results

Other Data/Outcomes Length of stay: DialysisControl 6 +/- 3 days13 +/- 18 daysp=0.017 No major complications in dialysis group Results

Limitations Limited sample size Single center Study not blinded Not compared to double dose mucomyst Did not use visipaque Only chose advanced renal disease Strong Endpoints? Discussion

Prophylactic HD in Advanced CKD Following Coronary Angiography: – Reduces discharge and maximum creatinine values – Probably reduces hospital stay – Probably prolongs need for permanent dialysis Conclusions

Prophylactic HD in Advanced CKD Following Coronary Angiography: – ? Effects on mortality, CV events – ? Effects on long term dialysis needs Conclusions

Will This Change How You Practice? Discussion